scholarly journals Increased Density of the Liver and Amiodarone-Associated Phospholipidosis

2009 ◽  
Vol 2009 ◽  
pp. 1-3 ◽  
Author(s):  
Sunao Kojima ◽  
Shinobu Kojima ◽  
Hirofumi Ueno ◽  
Motohiro Takeya ◽  
Hisao Ogawa
Keyword(s):  
Ventricular Tachycardia ◽  
Case Report ◽  
Liver Function ◽  
Liver Biopsy ◽  
Liver Tissue ◽  
Liver Enzymes ◽  
Ct Scanning ◽  
Computed Tomographic ◽  
Unenhanced Ct ◽  
Periodic Monitoring

This is a case report in which a 60-year-old man who suffered from ventricular tachycardia with dilated cardiomyopathy was prescribed amiodarone. After taking amiodarone, liver enzymes were increased and computed tomographic (CT) scanning of the abdomen showed a significant increase in the density of the liver without contrast medium. He was suspected as hemochromatosis and liver biopsy was performed. An abnormal high density of liver tissue may be observed in an unenhanced CT in patients treated with amiodarone and we suggest that periodic monitoring of liver function and/or liver biopsy is warranted before an irreversible stage is reached.

scholarly journals Descending Necrotising Mediastinitis: A Case Report Illustrating a Trend in Conservative Management

2012 ◽  
Vol 2012 ◽  
pp. 1-4 ◽  
Author(s):  
B. A. P. Jayasekera ◽  
O. T. Dale ◽  
R. C. Corbridge
Keyword(s):  
Case Report ◽  
Mortality Rate ◽  
Surgical Intervention ◽  
Case Series ◽  
Ct Scanning ◽  
Posterior Mediastinum ◽  
Chest Drain ◽  
Conservative Approach ◽  
Computed Tomographic ◽  
Contrast Enhanced

The mortality rate from descending necrotising mediastinitis (DNM) has declined since its first description in 1938. The decline in mortality has been attributed to earlier diagnosis by way of contrast-enhanced computed tomographic (CT) scanning and aggressive surgical intervention in the form of transthoracic drainage. We describe a case of DNM with involvement of anterior and posterior mediastinum down to the diaphragm, managed by cervicotomy and transverse cervical drainage with placement of corrugated drains and a pleural chest drain, with a delayed mediastinoscopy and mediastinal drain placement. We advocate a conservative approach with limited debridement and emphasis on drainage of infection in line with published case series.

scholarly journals Acute Isolated Hyperbilirubinemia as a Presentation of Alcoholic Liver Disease: A Case Report and Literature Review

2018 ◽  
Vol 2018 ◽  
pp. 1-3
Author(s):  
Muhammad Rajib Hossain ◽  
Ramesh Kumar Pandey ◽  
Mohammad Faridul Islam ◽  
Praveen Datar ◽  
Vijay Gayam ◽  
...  
Keyword(s):  
Case Report ◽  
Liver Disease ◽  
Alcohol Consumption ◽  
Liver Function ◽  
Liver Biopsy ◽  
Literature Review ◽  
Autoimmune Hepatitis ◽  
Alcoholic Liver Disease ◽  
Chronic Alcoholism ◽  
Extrahepatic Cholestasis

Isolated hyperbilirubinemia as a manifestation of alcoholic liver disease without significant liver abnormalities is seen very rarely. We report such a case where a patient with chronic alcoholism presented to the ER with acute jaundice with bilirubin of 24.8 mg/dl, predominantly conjugated in nature along with mild elevation of AST (76 IU/L). There were no other abnormalities of the liver function. The patient underwent extensive laboratory and imaging tests that excluded extrahepatic cholestasis, viral and autoimmune hepatitis, ischemic hepatitis, and so forth. Liver biopsy excluded hemochromatosis, dysplasia, or malignancy and other differentials. Bilirubin gradually trended down to 7.3 mg/dl when alcohol consumption was stopped.

scholarly journals Trichrome-positive intrahepatic cytoplasmic globules are potential histopathological clue for COVID-19-induced hepatitis: a case report

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Dina Sweed ◽  
Mohamed Ramadan El Shanshory ◽  
Eman Mohammed Elaskary ◽  
Hassnaa Atef Hassan ◽  
Enas Sweed ◽  
...  
Keyword(s):  
Case Report ◽  
Severe Acute Respiratory Syndrome ◽  
Liver Biopsy ◽  
Respiratory System ◽  
Hepatitis A ◽  
Liver Enzymes ◽  
Dramatic Improvement ◽  
Case Presentation ◽  
Elevated Liver Enzymes ◽  
History Of

Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection mainly affects respiratory system. Later, liver affection has also been reported in the form of marked elevated liver enzymes. However, the association of coronavirus disease-19 (COVID-19) and autoimmune diseases is not clear. Case presentation A female patient with a known history of autoimmune hemolytic anemia (AIHH) for which she was treated with prednisolone was admitted for uncontrolled anemia followed by fever and elevated liver enzymes. All the laboratory and radiological investigations were not typical for COVID-19 or any other etiology. Liver biopsy revealed numerous pale eosinophilic trichrome-positive intracytoplasmic globules. The pathology raised the suspicion for SARS-CoV-2-associated hepatitis, which was confirmed by a positive IgG titer. The patient showed a dramatic improvement on the maintenance dose of prednisolone. Conclusions AIHA patients co-infected with SARS-CoV-2 may be at risk of uncontrolled disease and should continue their treatment regimen. Histopathology has a role in the diagnosis of liver affection due to SARS-CoV-2 infection.

scholarly journals COVID-19 in a Patient with Liver Cirrhosis

2020 ◽  
Vol 29 (2) ◽  
pp. 263-266 ◽  
Author(s):  
Edita Kreivenaite ◽  
Rolandas Gedgaudas ◽  
Irena Valantiene ◽  
Aukse Mickiene ◽  
Juozas Kupcinskas
Keyword(s):  
Liver Cirrhosis ◽  
Case Report ◽  
Severe Acute Respiratory Syndrome ◽  
Liver Function ◽  
Liver Enzymes ◽  
Liver Function Tests ◽  
Abnormal Liver Function ◽  
Fever Onset ◽  
First Case ◽  
Clinical Consequences

The outbreak of coronavirus disease 2019 (COVID-19) has recently become a serious issue affecting thousands of people worldwide. It is known that a substantial proportion of patients infected with COVID-19 have abnormal liver function tests; however, the consequences of this information is still not clear. Here we present the first case report of a patient with liver cirrhosis and COVID-19 in our centre. Resolution of COVID-19 symptoms was observed after six days of fever onset. We observed only slight fluctuations of liver enzymes, bilirubin levels and INR without clinical consequences in our case. We suggest testing for severe acute respiratory syndrome coronavirus on any cirrhotic patient on initial presentation, even without symptoms of COVID-19 in areas where the epidemic was prevalent.

Iron Chelation Therapy with Deferasirox (Exjade®, ICL670) or Deferoxamine Results in Reduced Hepatocellular Inflammation and Improved Liver Function in Patients with Transfusion-Dependent Anemia.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 823-823 ◽  
Author(s):  
P. Brissot ◽  
B. Turlin ◽  
G.L. Forni ◽  
G. Alimena ◽  
G. Quarta ◽  
...  
Keyword(s):  
Liver Function ◽  
Liver Biopsy ◽  
Serum Ferritin ◽  
Liver Tissue ◽  
Chelation Therapy ◽  
Iron Concentration ◽  
Iron Chelation ◽  
Iron Chelation Therapy ◽  
Hepatocellular Injury ◽  
Liver Iron

Abstract Transfusional hemosiderosis is often associated with hepatic siderosis or infection with hepatotropic viruses, resulting in hepatocellular injury and progression to chronic liver disease. Liver biopsy is the method of choice for directly assessing damage; scales have been developed to measure necroinflammatory activity (grading) and tissue fibrosis (staging). Iron chelation therapy is historically known to decrease morbidity associated with hepatosiderosis. Aim: To assess 1 year’s chelation therapy with the novel once-daily oral chelator, deferasirox (DSX), or the current standard deferoxamine (DFO), on pathology of liver tissue in chronically transfused patients. Methods: Liver biopsy was performed at baseline and after 1 year in patients participating in DSX Studies 0107 (n=454) and 0108 (n=101). All patients, except 25 in 0107 and 3 in 0108, had liver tissue evaluated by pathology. In 0107, patients with β-thalassemia were randomized to DSX (5, 10, 20 or 30 mg/kg/day; n=224) or DFO (<25, 25–35, 35–50 and ≥ 50 mg/kg; n=230) according to baseline liver iron concentration (LIC). In 0108, patients with β-thalassemia unable to be treated with DFO (n=61) and patients with rare anemias (MDS, DBA and others) (n=40) were enrolled and received DSX only. Grading and staging were determined from biopsy by the Ishak method; LIC was measured in parallel by atomic absorption spectrometry. Results: DSX and DFO dose-dependently affected grading, which mirrored effects on LIC and serum ferritin. DSX 5 and 10 mg/kg increased these parameters, while stabilization and decreases were seen with the highest doses of both chelators, regardless of hepatitis C status. In 0107, a decrease in mean ±SD necroinflammatory score was noted with DSX 30 mg/kg (2.5 ±1.6 to 1.7 ±1.3, n=95) and DFO ≥ 50 mg/kg 5 days/week (2.1 ±1.6 to 1.4 ±1.3, n=95). Similar results were observed in 0108 for β-thalassemia (2.4 ±1.7 to 1.7 ±1.6, n=58) and rare anemia patients (1.8 ±1.5 to 1.5 ±1.3, n=40). This decrease was accompanied by dose-dependent modification of available liver enzyme levels in 0107 (Table); with a similar trend in 0108. No obvious modification of staging was observed after 1 year of treatment, suggesting that longer time periods are needed to observe potential reversal of fibrosis. Change in liver enzymes (ALT; U/L) by treatment (Study 0107) DSX, mg/kg DFO, mg/kg 5 10 20 30 <25 25–35 35–50 ≥ 50 n=8 n=43 n=64 n=107 n=6 n=28 n=88 n=107 Mean ± SD 34.9 21.9 3.6 −2.8 −13.9 −3.7 −2.8 −12.4 ±35.1 ±25.2 ±28.7 ±79.3 ±29.7 ±17.6 ±20.7 ±38.6 Median (range) 36.8 10.0 0.5 −8.0 −10.8 −1.8 −0.8 −9.5 (−19.0, 101.5) (−7.5, 105.0) (−111.5, 91.0) (−143.0, 711.0) (−61.0, 27.0) (−55.5, 32.0) (−93.5, 70.5) (−171.0, 193.3) Conclusions: Although the data show considerable variability, results suggest that chelation therapy with DSX or DFO is associated with reduced hepatocellular inflammation and improved liver function. These modifications appear to be linked with effects on LIC and serum ferritin levels.

Liver Biopsy Culture in the Diagnosis of Miliary Tuberculosis: A Case Report

1952 ◽  
Vol 22 (1) ◽  
pp. 124-127 ◽  
Author(s):  
John M. Rumball ◽  
George L. Baum
Keyword(s):  
Case Report ◽  
Liver Biopsy ◽  
Miliary Tuberculosis

Point ablation for macro-reentrant ventricular tachycardia associated with Ebstein’s anomaly and pulmonary atresia: a case report

2020 ◽  
pp. 1-3
Author(s):  
Keiko Toyohara ◽  
Yasuko Tomizawa ◽  
Morio Shoda
Keyword(s):  
Ventricular Tachycardia ◽  
Case Report ◽  
Catheter Ablation ◽  
Right Ventricle ◽  
Low Voltage ◽  
Pulmonary Atresia ◽  
Ebstein’S Anomaly ◽  
Ebstein's Anomaly ◽  
Slow Conduction ◽  
Hypoplastic Right Ventricle

Abstract We report a case with Ebstein’s anomaly and pulmonary atresia with sustained monomorphic ventricular tachycardia in a patient without a ventriculotomy history. In the low voltage area between the atrialised right ventricle and hypoplastic right ventricle, there was a ventricular tachycardia substrate and slow conduction. The tachycardia circuit was eliminated by a point catheter ablation at the area with diastolic fractionated potentials.

Ventricular tachycardia secondary to thyrotoxic periodic paralysis: A case report

2021 ◽  
Author(s):  
Juan Duarte Torres ◽  
Alexander Marschall ◽  
Cristina Fraile Sanz ◽  
Belen Biscotti Rodíl ◽  
Hugo del Castillo Carnevali ◽  
...  
Keyword(s):  
Ventricular Tachycardia ◽  
Case Report ◽  
Periodic Paralysis ◽  
Thyrotoxic Periodic Paralysis
Sign in / Sign up

Export Citation Format

Share Document